Page last updated: 2024-12-11

kendomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

kendomycin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5472093
CHEBI ID191052
SCHEMBL ID4748055
MeSH IDM0466201

Synonyms (15)

Synonym
kendomycin
183202-73-5
tan 2162
nsc716244
nsc-716244
1,9-diepoxybenzocyclooctadecen-3(5h)-one, 6,7,8,9,10,11,12,15,16,17,18,19-dodecahydro- 4,7,19-trihydroxy-2,6,8,12,14,16,18-heptamethyl-, (5r,6r,7s,8r,9r,12s,13e,16s,18s,19s)-
(1r,9s,10s,12s,14e,16s,19r,20r,21s,22r)-3,9,21-trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.16,9.02,7]tetracosa-2,5,7,14-tetraen-4-one
CHEBI:191052
kendomycin from streptomyces violaceoruber
SCHEMBL4748055
HY-121300
CS-0081390
Q262602
DTXSID901043890
AKOS040748665

Research Excerpts

Overview

Kendomycin is a small-molecule natural product that has gained significant attention due to reported cytotoxicity against pathogenic bacteria and fungi. It is produced by various Streptomyces strains. Kendomycin has a unique quinone methide ansa structure and various biological properties.

ExcerptReferenceRelevance
"Kendomycin is a small-molecule natural product that has gained significant attention due to reported cytotoxicity against pathogenic bacteria and fungi as well as a number of cancer cell lines. "( Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
Estoppey, D; Filipuzzi, I; Hoepfner, D; Kellosalo, J; Knapp, B; Lochmann, T; Meissner, A; Paavilainen, VO; Pistorius, D; Tranter, D, 2020
)
3.44
"Kendomycin is a novel polyketide that has a unique quinone methide ansa structure and various biological properties."( Investigations to the Antibacterial Mechanism of Action of Kendomycin.
Bischoff, M; Chatterjee, I; Elnakady, YA; Herrmann, M; Josten, M; Müller, R; Rohde, M; Sahl, HG, 2016
)
1.4
"Kendomycin is a bioactive polyketide that is produced by various Streptomyces strains. "( A type I/type III polyketide synthase hybrid biosynthetic pathway for the structurally unique ansa compound kendomycin.
Bode, HB; Kochems, I; Müller, R; Wenzel, SC, 2008
)
2
"Kendomycin is a novel polyketide having a unique quinone methide ansa structure and an impressive biological profile. "( In pursuit of a competitive target: total synthesis of the antibiotic kendomycin.
Magauer, T; Martin, HJ; Mulzer, J, 2010
)
2.04

Treatment

ExcerptReferenceRelevance
"Most kendomycin-treated cells displayed incomplete septa with abnormal morphology."( Investigations to the Antibacterial Mechanism of Action of Kendomycin.
Bischoff, M; Chatterjee, I; Elnakady, YA; Herrmann, M; Josten, M; Müller, R; Rohde, M; Sahl, HG, 2016
)
1.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzofurans
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bcl-2-like protein 1Homo sapiens (human)IC50 (µMol)12.30000.00031.04829.5400AID348912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bcl-2-like protein 1Homo sapiens (human)Kd1,179.00000.00010.90252.8000AID348914; AID348915
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (43)

Processvia Protein(s)Taxonomy
response to cytokineBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsBcl-2-like protein 1Homo sapiens (human)
ovarian follicle developmentBcl-2-like protein 1Homo sapiens (human)
in utero embryonic developmentBcl-2-like protein 1Homo sapiens (human)
release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
endocytosisBcl-2-like protein 1Homo sapiens (human)
germ cell developmentBcl-2-like protein 1Homo sapiens (human)
spermatogenesisBcl-2-like protein 1Homo sapiens (human)
male gonad developmentBcl-2-like protein 1Homo sapiens (human)
apoptotic mitochondrial changesBcl-2-like protein 1Homo sapiens (human)
fertilizationBcl-2-like protein 1Homo sapiens (human)
regulation of cytokinesisBcl-2-like protein 1Homo sapiens (human)
positive regulation of mononuclear cell proliferationBcl-2-like protein 1Homo sapiens (human)
ectopic germ cell programmed cell deathBcl-2-like protein 1Homo sapiens (human)
regulation of growthBcl-2-like protein 1Homo sapiens (human)
negative regulation of apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
dendritic cell proliferationBcl-2-like protein 1Homo sapiens (human)
response to cycloheximideBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane permeabilityBcl-2-like protein 1Homo sapiens (human)
epithelial cell proliferationBcl-2-like protein 1Homo sapiens (human)
negative regulation of developmental processBcl-2-like protein 1Homo sapiens (human)
neuron apoptotic processBcl-2-like protein 1Homo sapiens (human)
defense response to virusBcl-2-like protein 1Homo sapiens (human)
regulation of mitochondrial membrane potentialBcl-2-like protein 1Homo sapiens (human)
cellular response to amino acid stimulusBcl-2-like protein 1Homo sapiens (human)
cellular response to alkaloidBcl-2-like protein 1Homo sapiens (human)
cellular response to gamma radiationBcl-2-like protein 1Homo sapiens (human)
apoptotic process in bone marrow cellBcl-2-like protein 1Homo sapiens (human)
negative regulation of release of cytochrome c from mitochondriaBcl-2-like protein 1Homo sapiens (human)
dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
hepatocyte apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of execution phase of apoptosisBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
negative regulation of protein localization to plasma membraneBcl-2-like protein 1Homo sapiens (human)
negative regulation of reproductive processBcl-2-like protein 1Homo sapiens (human)
negative regulation of dendritic cell apoptotic processBcl-2-like protein 1Homo sapiens (human)
negative regulation of extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayBcl-2-like protein 1Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damageBcl-2-like protein 1Homo sapiens (human)
extrinsic apoptotic signaling pathway in absence of ligandBcl-2-like protein 1Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processBcl-2-like protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingBcl-2-like protein 1Homo sapiens (human)
protein kinase bindingBcl-2-like protein 1Homo sapiens (human)
identical protein bindingBcl-2-like protein 1Homo sapiens (human)
BH3 domain bindingBcl-2-like protein 1Homo sapiens (human)
BH domain bindingBcl-2-like protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytoplasmBcl-2-like protein 1Homo sapiens (human)
mitochondrionBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial inner membraneBcl-2-like protein 1Homo sapiens (human)
mitochondrial matrixBcl-2-like protein 1Homo sapiens (human)
endoplasmic reticulumBcl-2-like protein 1Homo sapiens (human)
centrosomeBcl-2-like protein 1Homo sapiens (human)
cytosolBcl-2-like protein 1Homo sapiens (human)
synaptic vesicle membraneBcl-2-like protein 1Homo sapiens (human)
nuclear membraneBcl-2-like protein 1Homo sapiens (human)
Bcl-2 family protein complexBcl-2-like protein 1Homo sapiens (human)
mitochondrial outer membraneBcl-2-like protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID348915Inhibition of interaction between Bcl-xl and Bak by surface plasmon resonance assay2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID1651704Metal chelating activity assessed as compound-Cu2+ complex formation by UV-Vis spectrophotometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID348912Inhibition of interaction between GST-tagged Bcl-xl and Bak by fluorescence polarization assay2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID1651703Metal chelating activity assessed as compound-Fe2+ complex formation by UV-Vis spectrophotometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651708Inhibition of protein biogenesis in human HCT116 cells assessed as reduction in total protein level at 100 to 1000 nM preincubated for 30 mins followed by addition of 35S-labeled methionine/cysteine and measured after 90 mins by autoradiography2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651718Antibacterial activity against Bacillus subtilis assessed as reduction in microbial growth in presence of CuCl2 by serial dilution method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651714Metal chelating activity assessed as compound-Mg+ complex formation by UV-Vis spectrophotometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID348909Antibacterial activity against methicillin-resistant Staphylococcus aureus STA MU502008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID348914Inhibition of interaction between GST-tagged Bcl-xl and Bak by surface plasmon resonance assay2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID1651720Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs in presence of CuCl2 by AlamarBlue assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651717Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs in presence of FeCl2 by AlamarBlue assay2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651716Antifungal activity against Saccharomyces cerevisiae assessed as reduction in microbial growth in presence of FeCl22020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651712Metal chelating activity assessed as compound-Fe3+ complex formation by UV-Vis spectrophotometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651722Binding affinity to Fe2+ ion assessed as compound-Fe2+ formation by 1H NMR spectroscopy2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651709Inhibition of protein biogenesis in human HCT116 cells assessed as reduction in secreted protein level at 100 to 1000 nM preincubated for 30 mins followed by addition of 35S-labeled methionine/cysteine and measured after 90 mins by autoradiography2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651721Binding affinity to Cu2+ ion assessed as compound-Cu2+ formation by 1H NMR spectroscopy2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651715Antibacterial activity against Bacillus subtilis assessed as reduction in microbial growth in presence of FeCl2 by serial dilution method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651719Antifungal activity against Saccharomyces cerevisiae assessed as reduction in microbial growth in presence of CuCl22020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID507144Induction of cell cycle arrest in human HeLa cells assessed as accumulation at G1 arrest at 10 uM after 20 hrs by Hoescht 33342 staining2008Nature chemical biology, Jan, Volume: 4, Issue:1
Integrating high-content screening and ligand-target prediction to identify mechanism of action.
AID1651713Metal chelating activity assessed as compound-calcium complex formation by UV-Vis spectrophotometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651707Inhibition of proteosome in human K562 cells assessed as reduction in UbG76V-GFP degradation at 2.5 to 10 uM incubated for 4 hrs by flow cytometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID1651705Inhibition of proteosome in HEK293T cells assessed as reduction in UbG76V-GFP degradation at 250 nM incubated for 4 hrs by flow cytometric analysis2020Journal of natural products, 04-24, Volume: 83, Issue:4
Kendomycin Cytotoxicity against Bacterial, Fungal, and Mammalian Cells Is Due to Cation Chelation.
AID348910Cytotoxicity against human HepG2 cells2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID348911Chemical stability assessed as half life by HPLC2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
AID348913Cytotoxicity against human A549 cells2008Bioorganic & medicinal chemistry letters, Nov-01, Volume: 18, Issue:21
Interaction of kendomycin and semi-synthetic analogues with the anti-apoptotic protein Bcl-xl.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's18 (60.00)29.6817
2010's10 (33.33)24.3611
2020's2 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.58 (24.57)
Research Supply Index3.43 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]